Hepion Pharmaceuticals Stock Performance
| HEPA Stock | USD 0.42 0.03 7.18% |
The company retains a Market Volatility (i.e., Beta) of -0.72, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Hepion Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Hepion Pharmaceuticals is likely to outperform the market. At this point, Hepion Pharmaceuticals has a negative expected return of -4.14%. Please make sure to check out Hepion Pharmaceuticals' value at risk and the relationship between the kurtosis and market facilitation index , to decide if Hepion Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Hepion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in June 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:50 | Dividend Date 2019-06-03 | Last Split Date 2025-03-18 |
1 | Disposition of 16666 shares by Sapirstein James of Hepion Pharmaceuticals at 1.5 subject to Rule 16b-3 | 02/28/2025 |
2 | Hepion Pharmaceuticals releases unaudited balance sheet - Investing.com | 03/04/2025 |
3 | Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split Effective March 17, 2025 - Nasdaq | 03/17/2025 |
4 | Disposition of tradable shares by Cerrone Gabriel of Hepion Pharmaceuticals subject to Rule 16b-3 | 03/21/2025 |
5 | Hepion Pharmaceuticals Delays Annual Report Filing - TipRanks | 04/01/2025 |
6 | Hepion Pharmaceuticals Announces 9M Public Offering Launch | 04/09/2025 |
7 | Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to ... | 05/07/2025 |
| Begin Period Cash Flow | 14.8 M |
Hepion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 855.00 in Hepion Pharmaceuticals on February 8, 2025 and sell it today you would lose (816.00) from holding Hepion Pharmaceuticals or give up 95.44% of portfolio value over 90 days. Hepion Pharmaceuticals is currently does not generate positive expected returns and assumes 11.3033% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Hepion, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hepion Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hepion Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hepion Pharmaceuticals, and traders can use it to determine the average amount a Hepion Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3661
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HEPA |
Estimated Market Risk
| 11.3 actual daily | 96 96% of assets are less volatile |
Expected Return
| -4.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.37 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hepion Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hepion Pharmaceuticals by adding Hepion Pharmaceuticals to a well-diversified portfolio.
Hepion Pharmaceuticals Fundamentals Growth
Hepion Stock prices reflect investors' perceptions of the future prospects and financial health of Hepion Pharmaceuticals, and Hepion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hepion Stock performance.
| Return On Equity | -4.87 | ||||
| Return On Asset | -1.23 | ||||
| Current Valuation | 7.31 M | ||||
| Shares Outstanding | 10.98 M | ||||
| Price To Earning | (3.01) X | ||||
| Price To Book | 2.11 X | ||||
| EBITDA | (19.35 M) | ||||
| Net Income | (13.19 M) | ||||
| Cash And Equivalents | 59.15 M | ||||
| Cash Per Share | 0.78 X | ||||
| Total Debt | 2.9 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.77 X | ||||
| Book Value Per Share | (25.57) X | ||||
| Cash Flow From Operations | (18.22 M) | ||||
| Earnings Per Share | (5,368) X | ||||
| Market Capitalization | 3.12 M | ||||
| Total Asset | 1.61 M | ||||
| Retained Earnings | (237.82 M) | ||||
| Working Capital | (1.53 M) | ||||
| Current Asset | 4.82 M | ||||
| Current Liabilities | 1.81 M | ||||
About Hepion Pharmaceuticals Performance
By analyzing Hepion Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Hepion Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hepion Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hepion Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.18) | (7.77) | |
| Return On Capital Employed | 12.64 | 13.28 | |
| Return On Assets | (8.18) | (7.77) | |
| Return On Equity | 7.08 | 7.43 |
Things to note about Hepion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Hepion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hepion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hepion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Hepion Pharmaceuticals has high historical volatility and very poor performance | |
| Hepion Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (13.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hepion Pharmaceuticals currently holds about 59.15 M in cash with (18.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to ... |
- Analyzing Hepion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hepion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Hepion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hepion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hepion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hepion Pharmaceuticals' stock. These opinions can provide insight into Hepion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |